Follow us
Our Mission
In the battle against cancer, BIODENA CARE considers its mission as a succession of relays between Fundamental Scientific Knowledge on the one hand and "the Art and Science of Medicine" on the other.
The final relay, undoubtedly the most important, is the one that the Physician must carry out alone with his Patient, against the disease.
This is why, in order to never forget the Patient, we carry out our mission by exclusively serving Physicians with a single objective:
« To ensure that demonstrations of basic science become effective, reliable and accessible solutions, handed over to physicians for the benefit of their patients. »
Executive Team
Philippe Pourquier
CEO
Skills
-
AgroParisTech - Institut des Sciences et Industries du Vivant et de l'Environnement
-
Bachelor of Engineering (B.E.), Microbiology and Genetics of Microorganisms
Professional strength
-
More than 38 years of professional experience in the field of in vitro diagnostics.
-
Founder and Chief Executive Officer of Innovative Diagnotics, company who develops and produces ELISA and PCR reagents for the diagnosis of infectious zoonotic and veterinary diseases. ID employs over 170 staff members in its 5000 m² headquarters in Montpellier, France.
-
Chief Executive Officer of AFYIA Diagnostics, it aims to provide easy-to-use and affordable multiplex diagnostics for human syndromic infectious diseases.
-
Chief Executive Officer of ADELIS Technologies, a company developing an ultrasensitve and easy-to-use automat for size profiling of circulating DNA.
Nassima Mimoun
Managing Director
Skills
-
Medical Doctor
-
MBA from an international Business school in Paris ESCP Business School
-
Harvard Business School: Executive Leadership Program
Professional strength
-
25 years of experience in Pharma Industry.
-
Broad range of experiences across various therapeutic areas at regional and local level in multiple markets and mainly in oncology.
-
Solid experience in launching and successfully commercializing innovative products and identifying life cycle management opportunities.
-
Ability to work successfully with external stakeholders by integrating their insights.
-
Strong learning agility and a good track record in coming into new and challenging situations in both, strategic and operational roles using strong communication and interpersonal skills.
-
Diversity & Inclusion as a DNA to build right teams and talents working cross functionally.
-
Acting & leading by example. Supporting and driving transformations with flexibility and adaptability.
Alix De Jacquelot
Director of Business Development and Medical Partnerships
Skills
-
PharmD
-
Specialized in health product development
Professional strength
-
15 years' experience in pharmaceutical industry, including over 10 years in medical affairs, at regional, national and international levels.
-
Cross-functional collaboration to ensure pre-launch and launch of innovative drugs in various therapeutic areas, including immuno-oncology.
-
Good knowledge of clinical research, regulatory issues and market access.
-
Strategic vision, field experience, good listening and analytical skills.
Alexandre Prieur
Chief Scientific Officer
Skills
-
Scientific Director since 2012
-
20 years in cancer research
-
8 years of R&D specific to hPG80 (extra-cellular circulating progastrin)
-
PhD in Oncology since 2005 (Paris XI University)
-
Master - Innovation, Valorization, Partnerships (Montpellier University) in 2013
Professional strength
-
12 years of fundamental research as a researcher in cancer research institutes in Europe.
-
8 years of R&D in biotechnology companies as Chief Scientific Officer (diagnostic and therapy).
Results
-
Listed as inventor for 8 patent applications, including 7 on interaction between hPG80 and cancer.
-
Author of 10+ publications in peer-reviewed journals in the field of cancer.
-
Co-editor at Frontiers in Oncology on the Research Topic “Therapeutic Targeting of Cancer Stem Cells- The Current State of the Art “ in 2019.
François Fabre
Chief Financial and Operational Officer
Skills
-
Administrator of the group entities
-
Fundraising lead
-
Specialist in business management
-
Master's degree in international business
Professional strength
-
8 years as managing director or general manager of companies.
-
5 years in cash and investment management.
Results
-
Fundraising actions up to 26 M €.
-
Drastic cost management to ensure the sustainability of this company.
Monica Cappellini
Development and production manager
Skills
-
7 years of experience in R&D and production specific to hPG80
-
PhD in Neuroscience (University of Montpellier)
Professional strength
-
19 years of experience in start-up companies as in vivo and/or laboratory manager.
-
Strong team management and project management.
-
Implementation and maintenance of quality system according to ISO 13485.
Results
-
Co-author in several articles related to hPG80.
-
Successful launch of the DxPG80.Lab kit.
The dream of a scientist, the fight of a woman
Dominique Joubert
Senior Scientist Consultant
Dominique Joubert is a scientist with a PhD in biology and over 40 years of experience in academic and fundamental research. Between 1991 and 2011, she served as Director of Research at Inserm (France) and Director of the Oncology Department at the IGF, a Joint Research Unit of CNRS, INSERM, and the University of Montpellier.
Throughout her career, Dominique Joubert has challenged the prevailing scientific dogma by maintaining her belief that cancer follows the "laws of the living" and is therefore reversible. This conviction led her to search for a "key" to this reversion.
In 2003, a groundbreaking observation was made in her lab on a protein that needed to exit the tumor cell and re-interact with it to exert its effect on the tumor. Dominique Joubert hypothesized that this protein, linked to disruptions in the Wnt signaling pathway (a major contributor to tumorigenesis), could be the key to reversing the tumor process.
Her bold approach was met with skepticism. She proposed that neutralizing this protein could regulate the very pathway that produced it—an idea her team found far-fetched. Despite the doubts, Dominique Joubert proceeded with the experiment. To the surprise of many, the results were conclusive, providing the first demonstration that a tumor mechanism could be reversed in solid tumors.
The protein in question is progastrin, the precursor of gastrin, which is found in the G cells of the stomach in healthy individuals and is absent from the bloodstream. However, in cancer patients, progastrin is secreted by tumor cells and is referred to as hPG80. Her research has shown that hPG80 is present in the blood of 83% of cancer patients, and that 100% of tumors produce this protein.
Dominique Joubert believes that this discovery will revolutionize cancer treatment. However, she recognizes the challenges ahead: the need to mobilize the necessary resources, expertise, and energy to ensure that this breakthrough in basic research translates into practical solutions for physicians and ultimately benefits patients.